4basebio expects to sustain DNA sales growth momentum in 2025
27th May 2025 11:57
(Alliance News) - 4basebio on Tuesday reported a wider pretax loss in 2024, despite higher revenue, and said it is optimistic about the year to come. Read More
(Alliance News) - 4basebio on Tuesday reported a wider pretax loss in 2024, despite higher revenue, and said it is optimistic about the year to come. Read More
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Secures good manufacturing practice, or GMP, certification for its UK DNA manufacturing facility from the UK Medicines & Healthcare Products Regulatory Agency. This authorises it to manufacture and supply investigational medicinal product drug substance and critical starting biological medicinal materials used in advanced therapy medicinal products from its Cambridge facility, says the firm. Adds that the certification strengthens its position in the advanced therapeutics field and progresses it towards commercialisation and patient care for a range of advanced therapies. Chief Executive Heikki Lanckriet says: "Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company." Read More
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Names Gabe Longoria as the new chief commercial officer. Longoria was previously CCO at Astrea Bioseparations Ltd. The appointment follows a GBP40 million investment into 4basebio by Elevate Medical Technologies and M&G Investment Management Ltd, which completed in November. This is a "key milestone" for the company. Read More
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Announces the supply of its HQ synthetic DNA to an unnamed "Tier 1 pharma company". Says the client will use the synthetic DNA in late preclinical studies for an mRNA vaccine program. Financial details of the contract were not provided by 4basebio. Read More
(Alliance News) - 4basebio PLC on Thursday noted a "key milestone" with its client, which is progressing into a phase one clinical trial. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
4basebio PLC - Cambridge, England-based life-science tech company with proprietary technologies in the field of DNA synthesis - Announces success in tender process to supply research and GMP-grade synthetic DNA for the development of RNA therapeutics and vaccines at the CPI's RNA Centre of Excellence. The CPI is a UK government-supported organisation which offers development and scale-up services to companies. The Centre for Excellence is the name for its Darlington manufacturing facility. Read More
4basebio PLC - Heidelberg, Germany-based life sciences company - Pretax loss in the six months to June 30 widens to GBP3.9 million from GBP2.7 million a year prior. Revenue grows 57% to GBP238,000 from GBP152,000. Research and non-captialised development expenses however increase 56% to GBP1.6 million from GBP1.0 million. Administrative expenses increase 23% to GBP1.6 million from GBP1.3 million, as sales and marketing expenses increase to GBP248,000 from GBP97,000. Looking ahead, expects to secure new clients in the second half of 2023. Read More
(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued last week and not separately reported by Alliance News: Read More
4basebio PLC - Heidelberg, Germany-based life sciences company - Teams up with the University of Alabama and England-based Teesside University for a research project on Neurofibromatosis type 1, or NF1. The two universities have received USD1 million from US-based Gilbert Family Foundation for a three-year research programme. It aims to "life-changing gene therapy with applicability to all NF1 patients," 4basebio says. The firm will produce a non-viral vector for the universities, it adds. Read More
4Basebio PLC - Heidelberg, Germany-based life sciences company - Nearly quintuples annual loss. 2021 pretax loss widens to GBP3.6 million from GBP716,000 in 2020. Revenue falls to GBP338,000 from GBP462,000 the year before. Research and development expenses grow to GBP1.6 million from GBP343,000. Administration costs rise to GBP1.7m from GBP516,000. "The group invested heavily during 2021," 4Basebio explains. 4Basebio listed on AIM in February of last year. Read More
4basebio PLC - Heidelberg, Germany-based life sciences company - On Wednesday expands its synthetic DNA product offering with the addition of its opDNA product and its oeDNA product. Chief Executive Heikki Lanckriet says: "The development of our DNA product range over the past twelve months underscores the flexibility of our technology and our ability to customise DNA for particular uses. We are able to modify our DNA constructs for an individual customer's specific application." Read More
IN BRIEF: 4basebio works with eTheRNA on research collaboration Read More
TRADING UPDATES: Pennpetro loss narrows; ADM Energy production down Read More
IN BRIEF: 4basebio develops pilot clean room project manufacturing DNA Read More
UK shareholder meetings calendar - next 7 days Read More
IN BRIEF: 4basebio UK Societas files patent application for osDNA Read More
BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall Read More
Life Sciences Firm 4basebio UK Societas Begins Trading On AIM Read More